Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial / 中华医学杂志(英文版)

BACKGROUND@#LY01005 (Goserelin acetate sustained-release microsphere injection) is a modified gonadotropin-releasing hormone (GnRH) agonist injected monthly. This phase III trial study aimed to evaluated the efficacy and safety of LY01005 in Chinese patients with prostate cancer.@*METHODS@#We conducted a randomized controlled, open-label, non-inferiority trial across 49 sites in China. This study included 290 patients with prostate cancer who received either LY01005 or goserelin implants every 28 days for three injections. The primary efficacy endpoints were the percentage of patients with testosterone suppression ≤50 ng/dL at day 29 and the cumulative probability of testosterone ≤50 ng/dL from day 29 to 85. Non-inferiority was prespecified at a margin of -10%. Secondary endpoints included significant castration (≤20 ng/dL), testosterone surge within 72 h following repeated dosing, and changes in luteinizing hormone, follicle-stimulating hormone, and prostate specific antigen levels.@*RESULTS@#On day 29, in the LY01005 and goserelin implant groups, testosterone concentrations fell below medical-castration levels in 99.3% (142/143) and 100% (140/140) of patients, respectively, with a difference of -0.7% (95% confidence interval [CI], -3.9% to 2.0%) between the two groups. The cumulative probabilities of maintaining castration from days 29 to 85 were 99.3% and 97.8%, respectively, with a between-group difference of 1.5% (95% CI, -1.3% to 4.4%). Both results met the criterion for non-inferiority. Secondary endpoints were similar between groups. Both treatments were well-tolerated. LY01005 was associated with fewer injection-site reactions than the goserelin implant (0% vs . 1.4% [2/145]).@*CONCLUSION@#LY01005 is as effective as goserelin implants in reducing testosterone to castration levels, with a similar safety profile.@*TRIAL REGISTRATION@#ClinicalTrials.gov, NCT04563936.

Long-term Surgical and Chemical Castration Deteriorates Memory Function Through Downregulation of PKA/CREB/BDNF and c-Raf/MEK/ERK Pathways in Hippocampus / 대한배뇨장애요실금학회지

PURPOSE: Goserelin is a drug used for chemical castration. In a rat model, we investigated whether surgical and chemical castration affected memory ability through the protein kinase A (PKA)/cyclic adenosine monophosphate response element-binding protein (CREB)/brain-derived neurotrophic factor (BDNF) and c-Raf/mitogen-activated protein kinases-extracellular signal–regulated kinases (MEK)/extracellular signal–regulated kinases (ERK) pathways in the hippocampus. METHODS: Orchiectomy was performed for surgical castration and goserelin acetate was subcutaneously transplanted into the anterior abdominal wall for chemical castration. Immunohistochemistry was done to quantify neurogenesis. To assess the involvement of the PKA/CREB/BDNF and c-Raf/MEK/ERK pathways in the memory process, western blots were used. RESULTS: The orchiectomy group and the goserelin group showed less neurogenesis and impaired short-term and spatial memory. Phosphorylation of PKA/CREB/BDNF and phosphorylation of c-Raf/MEK/ERK decreased in the orchiectomy and goserelin groups. CONCLUSIONS: Short-term memory and spatial memory were affected by surgical and chemical castration via the PKA/CREB/BDNF and c-Raf/MEK/ERK signaling pathways.

Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin / 한국유방암학회지

The luteinizing hormone-releasing hormone/androgen receptor (LHRH/AR) pathway is a promising treatment target in a subgroup of female patients with triple-negative breast cancer (TNBC). However, very little is known about the efficacy of this strategy in male patients with TNBC. In this report, we describe a male patient with AR-positive TNBC who was successfully treated using an LHRH agonist after pretreatment with several lines of chemotherapy and achieved a durable response. We also review the existing evidence supporting LHRH- and AR-targeted therapy for this rare disease.

Anti-Müllerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients / 北京大学学报(医学版)

OBJECTIVE@#To observe the dynamic change of anti-Müllerian hormone (AMH) in 1 year after chemotherapy which is the best biochemical marker of ovarian reserve in reproductive medicine setting and to evaluate the effect of gonadotropin-releasing hormone agonist (GnRHa)goserelin to prevent ovarian reserve function during (neo)adjuvant chemotherapy for young breast cancer patients.@*METHODS@#Between December 2015 and June 2017, 101 breast cancer patients of age ≤ 45 years with stages I to III had been enrolled. The patients were assigned without interference to receive either (neo) adjuvant chemotherapy with goserelin (goserelin group) or without goserelin (chemotherapy group) as their own selection. AMH and menstrual status were evaluated before, during and 0.5 year, 1 year after chemotherapy. Primary end point was the incidence of low AMH value (<0.4 μg/L) at the end of 1 year. Secondary end point was the incidence of amenorrhea (the absence of menses in the preceding 12 months after assignment).@*RESULTS@#In the study, 51 patients chose to join the chemotherapy group, while the other 50 patients selected goserelin to preserve their ovarian reserve function. More unmarried or childless, hormone receptors negative,receiving breast conservation therapy patients with earlier stage selected goserelin before chemotherapy. The incidence of low AMH value was significantly higher in chemotherapy group than in goserelin group (74.5% vs. 38.0%, P<0.001) in 1 year after chemotherapy. The incidence of amenorrhea was consistent with AMH (56.9% vs. 24.0%, P=0.001). And more patients' menstruation (78.9% vs. 54.5%) and AMH value (71.0% vs. 53.8%) recovered in goserelin group within 6 months after chemotherapy. In subgroup analysis, AMH and menstruation seemingly recovered more in goserelin group independent of age, chemotherapy regimen and use of tamoxifen. Especially, AMH value of 36.4% (8/22) patients in chemotherapy group and 18.4% (7/38) patients in goserelin group still maintained low level (<0.4 μg /L) although their menstruation had recovered 1 year after chemotherapy. In addition, 41 patients (20 patients in chemotherapy group, 21 patients in goserelin group) could be evaluated for the dynamic change of AMH and menstrual status during chemotherapy. The mean level of AMH in chemotherapy group declined rapidly to very low level before the 3rd cycle, while 70% of the patients kept presence of menstruation. At the same time, the mean level of AMH in goserelin group was still above 0.4 μg /L, but all of the patients had menopause.@*CONCLUSION@#Our study has offered evidence that Goserelin with chemotherapy could protect against ovarian reserve failure for young breast cancer patients, now that more patients' AMH value recovered earlier who had selected co-treatment. AMH may be a more precise marker than menstrual status to clinically evaluate ovarian reserve function pre-, during and post- chemotherapy.

Efficacy of Combined Aromatase Inhibitor and Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Metastatic Breast Cancer

PURPOSE: Endocrine therapy is the preferred treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC). We investigated the efficacy of combined aromatase inhibitor (AI) and luteinizing hormone-releasing hormone (LHRH) agonist in premenopausal patients with HR-positive MBC. METHODS: We retrospectively analyzed the medical records of 21 HR-positive premenopausal MBC patients treated with combined AI and LHRH agonist therapy. RESULTS: The median follow-up period was 32.9 months. The overall response rate was 47.6%, with three complete responses (14.3%) and seven partial responses (33.3%). Nine patients (42.9%) achieved stable disease lasting more than 6 months; thus, the clinical benefit rate was 90.4%. The median time to progression was 45.4 months. No patients experienced grade 3 or 4 toxicity. CONCLUSION: Combined AI and LHRH agonist treatment safely and effectively induced remission or prolonged disease stabilization, suggesting that this could be a promising treatment option for HR-positive premenopausal patients with MBC.

Tratamiento con goserelina y tasa de embarazos de pacientes con infertilidad debida a endometriosis leve-moderada / Goserelin treatment and pregnancy rate of patients with infertility due mild-moderate endometriosis

El objetivo de la investigación fue determinar la utilidad del tratamiento con goserelina en la tasa de embarazos en pacientes con infertilidad debida a endometriosis leve-moderada. Se realizó un estudio prospectivo, en el que se incluyó a 76 mujeres con diagnóstico de infertilidad y endometriosis leve-moderada que asistieron al Hospital Central Dr. Urquinaona. El grupo de estudio (grupo A; n = 42 pacientes) que fueron tratadas con goserelina de depósito por vía subcutánea, una vez al mes por 3 meses. Al reiniciar los ciclos menstruales, se realizó hiperestimulación ovárica controlada / inseminación intrauterina. En el grupo de control (grupo B; n = 34 pacientes) solo se realizó hiperestimulación ovárica controlada / inseminación intrauterina. Se analizó la tasa de embarazos. La tasa de embarazos en el grupo A fue de 35,7 % por paciente y 24,5 % por ciclo estimulado. En el grupo B, la tasa fue de 32,3 % por paciente y del 23,9 % por ciclo estimulado. La tasa en el grupo de pacientes tratadas con goserelina fue más alta en el grupo de pacientes no tratadas, pero estas diferencias no son estadísticamente significativas (p = ns). Se concluye que el tratamiento con goserelina por 3 meses no es útil en pacientes con infertilidad debida a endometriosis leve-moderada, ya que no produce un aumento significativo en la tasa de embarazos.

The objective of research was to determine the usefulness of goserelin in the pregnancy rate in patients with infertility due mild - moderate endometriosis. A prospective study was conducted in which 76 women with a diagnosis of infertility and mild-moderate endometriosis was included, who attended the Central Hospital Dr. Urquinaona. The study group (group A; n = 42 patients) were treated with goserelin depot subcutaneously once monthly for 3 months. Upon restarting menstrual cycles, controlled ovarian hyperstimulation / intrauterine insemination was performed. In the control group (group B, n = 34 patients), only controlled ovarian hyperstimulation / intrauterine insemination was performed. The pregnancy rate was analyzed. The pregnancy rate in group A was 35,7 % per patient and 24,5 % per stimulated cycle. In group B, the rate was 32,3 % per patient and 23,9 % per stimulated cycle. The rates in the group of patients treated with goserelin were higher in the group of untreated patients, but these differences were not statistically significant (p = ns). It is concluded that treatment with goserelin for 3 months is not useful in patients with infertility due mild - moderate endometriosis, as it does not produce a significant increase in the rate of pregnancy.

Clinical efficacy of integrated traditional Chinese and Western medicine for castration-resistant prostate cancer / 中华男科学杂志

Objective@#To investigate the clinical effects of integrated traditional Chinese and Western medicine in the treatment of castration-resistant prostate cancer (CRPC).@*METHODS@#A total of 54 CRPC patients were randomly divided into a control and a trial group, all treated by endocrine therapy (oral Bicalutamide at 50 mg per d plus subcutaneous injection of Goserelin at 3.6 mg once every 4 wk) and chemotherapy (intravenous injection of Docetaxel at 75 mg/m2 once every 3 wk plus oral Prednisone at 5 mg bid), while the latter group by Fuyang Huayu Prescription (a Traditional Chinese Medicine ［TCM］ prescription for tonifying yang and dispersing blood stasis) in addition, for a course of 24 weeks. Comparisons were made between the two groups of patients in the level of serum prostate-specific antigen (PSA), Karnofsky physical condition scores, function assessment of cancer therapy-prostate (FACT-P) scores, and TCM symptoms scores before and after 12 or 24 weeks of treatment.@*RESULTS@#Compared with the baseline, the serum PSA level was significantly decreased after 12 weeks of treatment both in the control (［25.9 ± 39.3］ vs ［20.0 ± 21.1］ μg/L, P 0.05). At 24 weeks, however, the PSA levels in the control and trial groups were slightly increased to (23.1 ± 28.4) and (19.6 ± 23.5) μg/L, respectively, with no statistically significant differences in between (P >0.05). Karnofsky, FACT-P and TCM symptoms scores were all markedly improved in the trial group after 12 weeks of treatment (P 0.05).@*CONCLUSIONS@#TCM Fuyang Huayu Prescription combined with endocrine therapy and chemotherapy is effective for CRPC.

Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study

OBJECTIVE: Tamoxifen is an estrogen receptor antagonist used to prevent recurrence of breast cancer, which may provoke depression and anxiety and increase follicle-stimulating hormone (FSH) to patients. We compared anxiety and depression symptoms and FSH levels who received conventional tamoxifen alone and combination treatment of goserelin, a gonadotropin-releasing hormone (GnRH) analogue, with tamoxifen. METHODS: Sixty-four premenopausal women with hormone receptor-positive early-stage breast cancer were included and were assigned randomly to receive either tamoxifen and goserelin combination or tamoxifen alone for 12 months. The participants were evaluated blindly using the Hamilton Depression and Anxiety Rating Scale, the Beck Depression Rating Scale, and the Albany Panic and Phobia Questionnaire (APPQ). Blood FSH levels were assessed at baseline, 6 and 12 months. RESULTS: A significant time×group difference was detected in the agoraphobia trends subscale of the APPQ and in FSH levels. The combination group showed significantly less increases in agoraphobia subscale of APPQ and greater decreases in FSH level than those in the tamoxifen-alone group from baseline to 12 months of treatment. No significant differences for age, tumor grade, body mass index, or family history were found at baseline between the two groups. CONCLUSION: Our results suggest that the combination treatment of tamoxifen and goserelin resulted in less agoraphobia than tamoxifen alone in premenopausal women with breast cancer, which may associated with FSH suppression of goserelin.

Efficacy and safety investigation of Kuntai capsule for the add-back therapy of gonadotropin releasing hormone agonist administration to endometriosis patients: a randomized, double-blind, blank- and tibolone-controlled study / 中华医学杂志(英文版)

<p><b>BACKGROUND</b>As a Chinese Traditional Medicine product, Kuntai capsule could improve the peri-menopausal symptoms in postmenopausal women. But it is still not clear whether Kuntai capsule has a good effect on alleviating peri-menopausal symptoms induced by gonadotropin releasing hormone agonist (GnRH-a) treatment. The purpose of this study was to investigate the clinical effectiveness and safety of Kuntai capsule, on peri-menopausal symptoms in endometriosis (EMS) patients, with postoperative GnRH-a treatment.</p><p><b>METHODS</b>Ninety EMS ovarian cyst women with postoperative GnRH-a administration were enrolled in the study, and were randomly divided into Kuntai group, Tibolone group, or blank Control group. The therapeutic strategy in Kuntai group was 4 Kuntai capsules tid,po for 12 weeks after the first GnRH-a injection, while Tibolone 2.5 mg qd, po for 12 weeks in Tibolone group. There was no drug addition in Control group. Climacteric complaints were evaluated by Kupperman menopausal index (KMI) and hot flash/sweating score. Liver and renal functions, lipid profile, serum sex hormone levels and endometrial thickness were measured, and the frequency of adverse events in Kuntai and Tibolone groups was recorded.</p><p><b>RESULTS</b>(1) Before GnRH-a therapy, the baseline parameter results were comparable in the three groups (P > 0.05). (2) After GnRH-a therapy, KMI and hot flash/sweating scores in all the three groups increased significantly (P < 0.05). At the 4 th week after GnRH-a therapy, KMI and hot flash/sweating score results were as follows: Control group > Kuntai group > Tibolone group (P < 0.05); at the 8 th and 12 th week after GnRH-a therapy, KMI and hot flash/sweating score in Control group were significantly higher than the other two groups (P < 0.05), and no significant difference was identified between Kuntai and Tibolone group (P > 0.05). (3) No statistical change took place in the liver and renal functions and lipid profile in all the three groups after the treatment (P > 0.05). (4) The posttherapeutic serum follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) level and endometrial thickness decreased significantly in all the three groups (P < 0.05). After therapy, serum E2 level in Tibolone group was obviously higher than the other two groups (P < 0.05), while FSH and LH levels were obviously lower (P < 0.05). (5) The incidence of vaginal bleeding, breast distending pain in Tibolne group was obviously higher than Kuntai group (P < 0. 05).</p><p><b>CONCLUSIONS</b>Kuntai capsule is effective on the peri-menopausal symptoms induced by postoperative GnRH-a administration to EMS patients, although its clinical effect might be a few weeks later than Tibolone. Kuntai capsule might be a little safer than Tibolone tablet.</p>

Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor-Positive Breast Cancer without Chemotherapy-Induced Amenorrhea / Journal of the Korean Cancer Association, 대한암학회지

PURPOSE: The purpose of this study was to assess the value of ovarian ablation using goserelin in premenopausal patients with stage II/III hormone receptor-positive breast cancer without chemotherapy-induced amenorrhea (CIA). MATERIALS AND METHODS: We retrospectively reviewed the data of breast patients treated between October 1999 and November 2007 without CIA. The Kaplan-Meier method was used for calculation of the survival rate. Log rank method and Cox regression analysis were used for univariate and multivariate prognostic analysis. RESULTS: The median follow-up period was 61 months. Initially, 353 patients remained without CIA after chemotherapy and 98 among those who received goserelin and tamoxifen (TAM). In univariate analysis, goserelin improved locoregional recurrence-free survival (LRFS) (98.9% vs. 94.1%, p=0.041), distant metastasis-free survival (DMFS) (85.4% vs. 71.9%, p=0.006), disease-free survival (DFS) (85.4% vs. 71.6%, p=0.005), and overall survival (OS) (93.5% vs. 83.5%, p=0.010). In multivariate analysis, goserelin treatment was an independent factor influencing DMFS (hazard ratio [HR], 1.603; 95% confidence interval [CI], 1.228 to 2.092; p=0.001), DFS (HR, 1.606; 95% CI, 1.231 to 2.096; p=0.001), and OS (HR, 3.311; 95% CI, 1.416 to 7.742; p=0.006). In addition, treatment with goserelin resulted in significantly improved LRFS (p=0.039), DMFS (p=0.043), DFS (p=0.036), and OS (p=0.010) in patients aged or = 40 years, goserelin only improved DMFS (p=0.028) and DFS (p=0.027). CONCLUSION: Ovarian ablation with goserelin plus TAM resulted in significantly improved therapeutic efficacy in premenopausal patients with stage II/III hormone receptor-positive breast cancer without CIA.

Cáncer de mama con Her-2-neu y receptores hormonales positivos: tratamiento sistémico primario, biopsia del ganglio centinela y hormonoterapia / Breast cancer Her2/neu and estrogen receptor-positive: systemic treatment, sentinel lymph node biopsy and hormonotherapy

La quimioterapia neoadjuvante aparece como una opción terapéutica interesante en determinados casos de cáncer de mama. En éstos, el momento de la realización de la biopsia del ganglio centinela supone un tema de controversia actual. Los tumores Her-2-neu y receptores estrogénicos positivos presentan cierta resistencia a la terapia hormonal especialmente con tamoxifeno. Se presenta un caso con co-expresión de Her-2-neu y receptores estrogénicos que se trata con quimioterapia neoadjuvante y biopsia de ganglio centinela previa. En un segundo tiempo, se realiza cirugía conservadora sobre la mama con linfadenectomía axilar, radioterapia y hormonoterapia con letrozol, complementada con goserelina y trastuzumab. La evolución posterior ha sido muy favorable.

Neoadjuvant chemotherapy is an interesting option in the therapy of some breast cancer cases. Cases in which the timing for sentinel lymph node biopsy is controversial. Co-expression of estrogen receptors and Her2/neu (c-erbB-2) in breast cancer may imply hormone resistance, especially to tamoxifen. We present a clinic case with co-expression of estrogen receptors and Her2/neu that was treated with neoadjuvant chemotherapy and previous sentinel lymph node biopsy followed by breast tumorectomy with axillar lymphadenectomy, radiotherapy and hormonotherapy with letrozol, geserelina and trastuzumab. A good treatment response was found.

Evolução da função pulmonar após tratamento com goserelina em pacientes com linfangioleiomiomatose / Evolution of pulmonary function after treatment with goserelin in patients with lymphangioleiomyomatosis

Nas células musculares lisas atípicas características da linfangioleiomiomatose (LAM) encontram-se receptores de estrogênio e progesterona, de modo que o tratamento anti-hormonal pode ser considerado uma opção, mas ainda com resultados controversos. O objetivo deste trabalho foi avaliar retrospectivamente parâmetros hormonais e espirométricos em nove mulheres com LAM após o tratamento com goserelina por um ano. Houve um aumento médio de 80 mL e 130 mL, respectivamente, em VEF1 e CVF, assim como bloqueio hormonal efetivo. Ainda não se pode excluir um potencial efeito favorável da utilização de análogos de hormônio liberador de gonadotrofina em pacientes com LAM, reforçando a necessidade de ensaios randomizados.

In the atypical smooth muscle cells that are characteristic of lymphangioleiomyomatosis (LAM), there are estrogen and progesterone receptors. Therefore, anti-hormonal therapy, despite having produced controversial results, can be considered a treatment option. The objective of this retrospective study was to evaluate hormonal and spirometric data for nine women with LAM after one year of treatment with goserelin. The mean increase in FEV1 and FVC was 80 mL and 130 mL, respectively. There was effective blockage of the hormonal axis. It is still not possible to exclude a potential beneficial effect of the use of gonadotropin-releasing hormone analogues in LAM patients, which underscores the need for randomized trials.

A Case of an Adolescent with Paraphilia with Depot GnRH Analogue (Goserelin) / 대한정신약물학회지

Paraphilia was a very treatment resistant psychiatric disorder. But new treatment strategies to paraphilia have been introduced recently. We report and review the effect of depot analogue (goserelin) administration in a 18 year-old adolescent with paraphilia. We administered goserelin 3.6 mg/month to him for 3 months, there were changes of scores in Clinical Global Improvement, Sex Addiction Screening Test, Freund Paraphilia Scales.

A Case of Cyclic Vomiting Syndrome Responding to Gonadotropin-Releasing Hormone Analogue

Cyclic vomiting syndrome (CVS) is a disorder characterized by recurrent episodes of incapacitating nausea and vomiting interspersed with symptom free periods. Common triggers of cyclic vomiting include noxious stress, excitement, fatigue and menstrual period. Here, we report a case of cyclic vomiting syndrome in adult patient characterized by stereotypical vomiting attack, occurring in every menstruation period. Recurrent vomiting episodes began 6 years ago and we treated this patient with subcutaneous injection of goserelin, a gonadotropin-releasing hormone analogue (GnRHa) and oral estrogen. After 4 months of therapy, she was symptom free for the following 5 years, even with the resumed normal menstruation. Recurrence of vom - iting attack with same pattern occurred 1 month before readmission. Treatment with intravenous lorazepam aborted vomiting, but could not prevent recurrences of vomiting and epigastric pain. We treated the patient with GnRHa and oral estradiol again which effectively prevented recurrence of the symptoms.

Dor mamária: propedêutica e terapêutica / Breast pain: propaedeutic and therapeutic

Mastalgia é um dos sintomas mais comuns em mulheres, tendo uma prevalência de 41 a 69% e pode se apresentar como um leve desconforto até dor severa, que interfere na qualidade de vida. A principal preocupação das pacientes que consultam por este sintoma é o medo do câncer. Essa é classificada em mastalgia cíclica, acíclica ou extramamária. Cíclica quando se apresenta no período pré-menstrual; na acíclica não há relação com o ciclo e, geralmente, acomete pacientes na pós-menopausa. A extramamária é a dor referida na mama, porém usualmente é de origem musculoesquelética. Na presença de achados clínicos e radiológicos normais, aproximadamente 85% das pacientes melhoram apenas com orientação e tranquilização, não necessitando de medicação. Foi realizada uma revisão sistemática para avaliar as possibilidades terapêuticas e seus níveis de evidência. Os anti-inflamatórios não esteróides tópico, para mastalgia cíclica ou acíclica, e o fitoterâpico Agnus castus, para mastalgia cíclica, demonstraram boa eficácia e tolerabilidade e podem ser usados como medida inicial. O tamoxifeno e o danazol são medicamentos eficazes, porém apresentam mais efeitos colaterais. Para casos especiais, ainda há a alternativa de usar bromocriptina e goserelina. O manejo da dor mamária pode ser sintetizado em três itens: excluir câncer, orientar e tranquilizar ao máximo e medicar ao mínimo.(AU)

Breast pain or mastalgia is one of the most common symptoms in women, with a prevalence ranging from 41 to 69%. It presents as a mild discomfort to severe pain, that interferes with the quality of life. The main concern of patients consulting for this symptom is the fear of cancer. It is classified as cyclical, acyclical or extra-mammary. When presented during the premenstrual period, it is cyclical; acyclical, when not cycle-related and usually affects patients in post-menopausal. Extra-mammary is the breast referred pain, but it is usually of muscle-skeptical origin. In the presence of normal clinical and radiological findings, approximately 85% of patients improve only with reassurance, not requiring medication. A systematic review was performed to assess the therapeutic possibilities and their evidence levels. Topical non-steroidal anti-inflammatory drugs, for cyclic or acyclic mastalgia, and the phytotherapic Agnus castus, for cyclic mastalgia, showed good efficacy and tolerability and can be used as an initial measure. Tamoxifen and danazol are effective drugs, but they present more side effects. For special cases, there is the alternative of using bromocriptin and goserelin. Breast pain management can be summarized in three items: exclude cancer, maximum reassurance and minimum medication.(AU)

Neoadjuvant hormonal deprivation for patients undergoing radical prostatectomy / 亚洲男科学杂志(英文版)

The purpose of this study is to evaluate the therapeutic effect of radical prostatectomy combined with preoperative neoadjuvant hormonal ablation therapy for prostate cancer (PCa). In this study, a total of 31 patients with local PCa underwent radical prostatectomy; of these, 12 patients underwent preoperative hormonal deprivation with a combination of goserelin and flutamide for a period of 5.6 months. Data regarding clinical characteristics were compared between the neoadjuvant therapy and radical prostatectomy groups. A total of 31 patients received pelvic lymph node clearance, and the rate of positive lymph nodes was 12.9% (4/31). Serum prostate-specific antigen (PSA) was 8.9 +/- 1.2 microg L(-1) after the neoadjuvant therapy and 0.4 +/- 0.3 microg L(-1) one month after the radical prostatectomy. There were significant differences in the positive surgical margins, seminal vesicle invasion and lymph node metastasis between the neoadjuvant therapy group (n = 12) and the radical prostatectomy group (n = 19, P < 0.01). The resulsts indicates that preoperative hormonal deprivation induced by goserelin and flutamide can decrease clinical and pathological staging, but assessment of its influence on long-term prognosis requires further study.

Ovarian reserve after prolonged down regulation of pituitary gland

The aim of this prospective study was to investigate the ovarian reserve and pituitary gland activity after prolonged down regulation with Goserelin for 2 months. Thirty patients with stage II-IV endometriosis received Goserelin [Zoladex] every 4 weeks]. The ovarian reserve was checked by measuring the anti-mullerian hormone [AMH] level every 4 weeks at the same time of checking the resting FSH, LH, and E2. The pituitary response to the Buserelin was assessed by measuring the FSH, LH and E2 one hour post 500ug Buserelin injection and before the scheduled Zoladex injection every 4 weeks. The ovarian reserve was not affected by prolonged down regulation with Goserelin. The pituitary gland achieved a profound degree of down regulation 4 weeks post Goserelin and maintained the same degree of down regulation following each subsequent injection. However the pituitary gland retains some degree of activity by responding to Buserelin and producing pulses of FSH and LH despite the profound down regulation

Emabarazo luego de tratamiento conservador de hiperplasia endometrial atípica compleja con goserelina: caso clínico / Pregnancy after conservative treatment of a complex atypical endometrial hyperplasia with goserelin: case report

Se presenta el caso de una paciente de 28 años de edad que consultó por deseos de embarazo luego de dos abortos consecutivos. La biopsia de endometrio reportó hiperplasia glandular simple con atipias focales. Se le indica medroxiprogesterona (60mg diarios) por 3 meses. Al finalizar el tratamiento se le realiza histeroscopia en la que se observa lesión sospechosa en cara anterior del endometrio que la biopsia reporta progreso de la lesión a hiperplasia endometrial glandular compleja con atipias. Recibe goserelina (Zoladex ®) 3.5 mg vía subcutánea mensual durante 6 meses después presenta una gestación sin complicaciones, que culmina en cesárea. Se realiza nueva biopsia del endometrio, y no presentó evidencias de la enfermedad. Una histeroscopia realizada 3 meses más tarde no se observa la lesión endometrial. La hiperplasia compleja con atipias puede ser tratada de forma conservadora con análogos de GnRH en pacientes con deseos de su procreación y bajo seguimiento histeroscópico.